Mei Mei Hu
Founder chez VAXXINITY, INC.
Fortune : 60 M $ au 29/02/2024
Profil
Fondateur de Vaxxinity, Inc, Mei Mei Hu est actuellement président, directeur général et administrateur de cette société. M. Hu est également membre du conseil d'administration de United BioPharma, Inc. Il a obtenu un diplôme de premier cycle à l'Université de Pennsylvanie et un diplôme d'études supérieures à la Harvard Law School.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
VAXXINITY INC CLASS A
57,67% | 31/12/2023 | 65 096 861 ( 57,67% ) | 56 M $ | 29/02/2024 |
VAXXINITY INC CLASS B
39,78% | 31/12/2023 | 5 518 961 ( 39,78% ) | 5 M $ | 29/02/2024 |
Postes actifs de Mei Mei Hu
Sociétés | Poste | Début |
---|---|---|
VAXXINITY, INC. | Founder | 01/01/2014 |
UNITED BIOPHARMA INC | Director/Board Member | 01/03/2020 |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Chief Executive Officer | - |
Anciens postes connus de Mei Mei Hu
Sociétés | Poste | Fin |
---|---|---|
Shen Lian Biotechnology Co. Ltd. | Director/Board Member | 01/01/2014 |
Formation de Mei Mei Hu
University of Pennsylvania | Undergraduate Degree |
Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
VAXXINITY, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
United BioPharma, Inc.
United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
Shen Lian Biotechnology Co. Ltd. |